Boston Scientific slides after quarterly sales of key products disappoint

Boston Scientific

04/02/2026 19:01

Updates

** Shares of medical device maker Boston Scientific BSX.N tumble 14% to $78.72

** Stock set for its biggest pct fall in over 5 years, if losses hold

** BSX expects 2026 adjusted EPS of $3.43 to $3.49, the midpoint of which is below analysts' average estimate of $3.47 - LSEG-compiled data

** Sees net sales growth between 10.5% and 11.5% for 2026, slower than its 19.9% growth in 2025

** Electrophysiology franchise (EP) sales of $890 million below Street estimates of $933 million, according to RBC analysts

** Sales of Watchman, co's stroke prevention device, came in 1% below consensus with U.S. market entirely responsible for the miss, at least three analysts said

** "Investors now have reason to question the trajectory of these two key growth drivers moving forward" - brokerage J.P. Morgan, referring to EP and Watchman businesses

** Stock recently traded at 26.1 times expected earnings, vs its five-year avg forward PE of 26.9, suggesting it may be close to fairly valued, per LSEG data

** BSX reports Q4 EPS of 80 cents vs. average estimate of 78 cents

** Shares fell ~7% in 2025

 (Reporting by Sahil Pandey, Sriparna Roy and Kamal Choudhury)

 ((Sahil.Pandey@thomsonreuters.com))